ALK translocation

Pt in her early 40s, extensively metastatic lung cancer, “no target” on a few diff attempts at DNA seq (editorializing - please don’t biopsy bone for lung cancer diagnosis!) or liquid biopsy, repeat tissue biopsy & RNA seq = EML4-ALK translocation! Christmas came early! #lcsm (@FordePatrick)

Very nice tool for selecting treatment for both ALK and ROS translocations #NSCLC #lungcancer #gbot https://t.co/Otzs3Gqr6A (@VinciusLorandi1)

Very nice tool for selecting treatment for both ALK and ROS translocations #NSCLC #lungcancer #gbot https://t.co/Otzs3GpTh2 (@VinciusLorandi1)

👏 to Holger and colegues. New classification of RCC: 👉New morphological entity: eosinophilic & cystic RCC 👉New molecular-defined RCC: ELOC-mutated, ALK-translocation, SMARCB1, TFEB-altered, FH-deficient 👉New: pRCC is 1 entity only https://t.co/bdjyk1OBPf (@ViktorGruenwald)

Our series supports organ sparing therapy for patients with localized inflammatory myofibroblastic tumors of the bladder. Extirpative surgery only for refractory cases; crizotinib for metastatic disease with ALK translocation https://t.co/EJ3co2O1Ut @pjhensley11 @CurtisPettaway1 (@UroDocAsh)

Our real world analysis of the prevalence of ALK translocations. While rare, 21.6% of young pts with lung cancer had an ALK mutation. Biomarker panel testing is necessary and urgent at diagnosis. #LCSM #ALK hahttps://www.oncotarget.com/article/28114/text/#.YY0laOE_zMo.twitter (@EricBernicker)

About 5% of tumors are ALK which are generally tic inversions or translocations in #lungcancer says ⁦@GRSimonMD⁩ with cochairs ⁦@edgardo_ny⁩ ⁦@LuisERaez1⁩ and Dr Chiappori ⁦@OncLiveSOSS⁩ #ipc #lcsm ⁦@AdventHealth⁩ ⁦@MoffittNews⁩ ⁦ (@donnashort)

NEED HELP: writing commentary on ALK-directed tx in non-NSCLC tumors. Anytone know if @theNCI MATCH trial arm for ALK translocation has been reported? Per websute seems like accrual complete in 2015. Also for @EORTC CREATE, anyone know where the non-PRCC type1 arms are published? (@montypal)

These curves are the difference in OS outcomes based on out of pocket costs for #LungCancer w/ #EGFR Mt or #ALK translocations. Small numbers, but these data are very instructive. We need to support our pts better @EGFRResisters @ALKLungCancer @alk_fusion @ASCO_pubs #JCOOP #LCSM (@CharuAggarwalMD)

We now have two FDA approved treatments for the 1L management of NSCLC harboring an ALK translocation. This is an interesting one - the toxicity profile of the two drugs is very different in my experience, so there could be a role for both here. (@Jbauml)